TEHRAN (Iran News) – COVIRAN vaccine closer to completing human trials. Eight thousand volunteers in four cities will receive the first dose of the COVIRAN vaccine on June 10, moving toward completing the third phase of human testing.
COVIRAN BAREKAT, the first coronavirus vaccine made by researchers at the Headquarters for Executing the Order of the Imam, was unveiled on December 29, 2020, and started to be mass-produced on March 29.
So far, injections have been performed on 10,500 volunteers in the provinces of Tehran and Alborz through the third phase of the human trial, Hassan Jalili, director of the vaccine research team, said.
The volunteers are announced to be 18-75 years old, he added.
“One million doses of the vaccine have been produced. By June, this number will reach 12 million doses per month, and in August, and by September we will produce 20 to 25 million doses of vaccine.”
South America, African countries, several neighboring and two European countries have asked to purchase COVIRAN vaccine, Jalili said.
Although, we are capable of exporting the vaccine, however, through the policies adopted by the Ministry of Health, no vaccine will be exported until the domestic need is fully met, he stated.
Health Minister Saeed Namaki announced that immunization against coronavirus by the domestic vaccine will start by the next week, ISNA reported on May 30.
Vaccination to end by late November
President Hassan Rouhani said on Saturday that If the volume of COVID-19 vaccine required by the country is provided, the vaccination of people with underlying diseases will be completed by late July, and the whole population will be vaccinated by late November.
To vaccinate people with underlying diseases, about 14-15 million doses of vaccine is required, while we now have 5 million doses, so another 10 million must be provided to complete the process by the end of July, then we will continue the process with foreign and domestic vaccines, he explained.
He expressed hope to start vaccination of the whole population by the end of the summer (September 23), noting that given the country’s ability of vaccine administration, vaccinating 500,000 people in 24 hours, the entire population can receive the vaccine within three to four months.
The second Iranian-made vaccine developed by the Razi Vaccine and Serum Research Institute (Razi Cov Pars) to be administered among the population in early August; which started the clinical trial on February 27, entered the second phase of the human trial on Friday.
Iran has also successfully completed the first phase of the human trial for Fakhra vaccine, the third domestically developed COVID-19 vaccine, named after nuclear scientist Mohsen Fakhrizadeh (he was assassinated in November 2020 near Tehran), that was unveiled and started the clinical trial on March 16.
“Osvid-19”, the fourth domestic vaccine produced by Osvah Pharmaceutical Company is also undergoing human trials, which will also be available in early September.
On May 24, the first coronavirus vaccine made by the private sector in Iran succeeded in receiving the code of ethics and entered the phase of clinical studies.